SEC Form 4	
------------	--

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287		
	Estimated average burg	den		
Filed nursuant to Section 16(a) of the Securities Exchange Act of 1934	hours per response:	0.5		
Filed oursuant to Section 16(a) of the Securities Exchange Act of 1934	. °			

I

	or Section 30(h) of the Investment Company Act of 1940	
1. Name and Address of Reporting Person <sup>*</sup> Swartz Robin	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Voyager Therapeutics</u> , Inc. [VYGR]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (First) (Middle) C/O VOYAGER THERAPEUTICS, INC.,	3. Date of Earliest Transaction (Month/Day/Year) 04/03/2023	X Officer (give title Other (specify below) below) Chief Operating Officer
64 SIDNEY STREET (Street)	4. If Amendment, Date of Original Filed (Month/Day/Year)	<ul> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person Form filed by More than One Reporting</li> </ul>
CAMBRIDGE MA 02139		Person
(City) (State) (Zip)	Rule 10b5-1(c) Transaction Indication         Check this box to indicate that a transaction was made pursuant t         satisfy the affirmative defense conditions of Rule 10b5-1(c). See I	o a contract, instruction or written plan that is intended to nstruction 10.
Table I - Non-Deriva	tive Securities Acquired, Disposed of, or Benef	icially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	04/03/2023		<b>S</b> <sup>(1)</sup>		1,259(1)	D	<b>\$7.83</b> <sup>(2)</sup>	71,617	D	


Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Expiration		6. Date Exerc Expiration Da (Month/Day/Y	7. Titl Amou Secur Unde Deriv Secur 3 and	int of rities rlying ative rity (Instr.	Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

## Explanation of Responses:

1. Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the Reporting Person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2023. The sales do not represent a discretionary trade by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.54 to \$8.18, inclusive. The Reporting Person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.



04/05/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).